JP2004506605A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004506605A5 JP2004506605A5 JP2001574101A JP2001574101A JP2004506605A5 JP 2004506605 A5 JP2004506605 A5 JP 2004506605A5 JP 2001574101 A JP2001574101 A JP 2001574101A JP 2001574101 A JP2001574101 A JP 2001574101A JP 2004506605 A5 JP2004506605 A5 JP 2004506605A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- composition
- amount
- succinic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- 229960001231 Choline Drugs 0.000 claims 6
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 claims 6
- 239000001384 succinic acid Substances 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 210000002381 Plasma Anatomy 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- ZKMDOYRDBAGOAD-UHFFFAOYSA-L butanedioate;2-hydroxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCO.C[N+](C)(C)CCO.[O-]C(=O)CCC([O-])=O ZKMDOYRDBAGOAD-UHFFFAOYSA-L 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims 1
- 229960003178 Choline Chloride Drugs 0.000 claims 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M Choline chloride Chemical group [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims 1
- 235000019743 Choline chloride Nutrition 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin resistance Diseases 0.000 claims 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L disodium butanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
Claims (11)
(a)コリン塩基またはその薬学的に許容できる塩;および
(b)コハク酸またはその薬学的に許容できる塩
ならびに薬学的に許容できる希釈剤またはキャリヤーを含み、ここで、(a)成分単独の量および(b)成分単独の量はその作用を達成するのに不充分であり;しかも(a)および(b)成分の合計量の作用が、個々に投与した(a)および(b)成分の該量を用いて達成できる作用の合計よりも大きい、上記組成物。A composition for achieving synergy to treat insulin resistance in a mammal in need thereof, comprising an effective amount of (a) a choline base or a pharmaceutically acceptable salt thereof; and (b) succinic acid Or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier, wherein (a) the amount of component alone and (b) the amount of component alone is insufficient to achieve its action. Yes; and wherein the effect of the total amount of components (a) and (b) is greater than the total effect achievable using the individually administered amounts of components (a) and (b).
(a)コリン塩基またはその薬学的に許容できる塩;および
(b)コハク酸またはその薬学的に許容できる塩
ならびに薬学的に許容できる希釈剤またはキャリヤーを含み、ここで、(a)成分単独の量および(b)成分単独の量はその作用を達成するのに不充分であり;しかも(a)および(b)成分の合計量の作用が、個々に投与した(a)および(b)成分の量を用いて達成できる作用の合計よりも大きい、上記組成物。A composition for achieving synergy to treat diabetes mellitus in a mammal in need thereof, wherein said mammal has an effective amount of (a) a choline base or a pharmaceutically acceptable salt thereof; and (b) Succinic acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier, wherein the amount of component (a) alone and the amount of component (b) alone are not sufficient to achieve the action. A composition as described above, which is sufficient; and wherein the effect of the total amount of components (a) and (b) is greater than the total effect achievable using the amounts of components (a) and (b) administered individually.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU2000/000122 WO2001076583A1 (en) | 2000-04-10 | 2000-04-10 | Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004506605A JP2004506605A (en) | 2004-03-04 |
JP2004506605A5 true JP2004506605A5 (en) | 2005-02-03 |
JP3944393B2 JP3944393B2 (en) | 2007-07-11 |
Family
ID=20129496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001574101A Expired - Fee Related JP3944393B2 (en) | 2000-04-10 | 2000-04-10 | Synergistic composition comprising choline base and succinic acid for insulin resistance and diabetes |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1272171A1 (en) |
JP (1) | JP3944393B2 (en) |
KR (1) | KR20020089444A (en) |
CN (1) | CN1452482A (en) |
AU (1) | AU2000263274A1 (en) |
BR (1) | BR0017206A (en) |
CA (1) | CA2404864A1 (en) |
WO (1) | WO2001076583A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003236156A1 (en) * | 2003-04-24 | 2005-01-04 | Shin-Jen Shiao | Pharmaceutical compositions used for immune disease treatment and improvement |
EA017094B1 (en) * | 2007-08-02 | 2012-09-28 | Игорь Анатольевич Помыткин | Pharmaceutical compositions for intranasal administration comprising choline salts of succinic acid |
JP5408261B2 (en) * | 2008-11-26 | 2014-02-05 | アナトリエヴィチ ポミトキン,イーゴリ | Choline salt of succinic acid for the treatment of depression, anxiety, schizophrenia, sleep disorders, and epilepsy |
US8314080B2 (en) | 2010-04-06 | 2012-11-20 | Kuwait University | Method of treating type I diabetes |
CN106727476A (en) * | 2016-12-09 | 2017-05-31 | 杨远志 | A kind of composition and its application in animal muscle fiber types is improved |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR6346669D0 (en) * | 1962-02-12 | 1973-06-14 | Squibb & Sons Inc | PROCESS OF PREPARING A STABLE PHARMACEUTICAL COMPOSITION OF HILLS OF HILLS |
JPS61171417A (en) * | 1985-01-23 | 1986-08-02 | Wakunaga Seiyaku Kk | Antidiabetic |
US6294520B1 (en) * | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
JPH03169498A (en) * | 1989-11-28 | 1991-07-23 | Yotsukaichi Gosei Kk | Water soluble flux for soldering |
JPH0586319A (en) * | 1991-09-27 | 1993-04-06 | Pentel Kk | Water-base ink composition |
US5895652A (en) * | 1996-07-29 | 1999-04-20 | Longevity Institute International | Method of metabolic adjuvanation and cellular repair |
CA2366073A1 (en) * | 1999-03-01 | 2000-09-08 | Olga Evgenievna Kolesova | Use of succinic acid or salts thereof and method of treating insulin resistance |
EP1165063A1 (en) * | 1999-04-05 | 2002-01-02 | Verteletsky, Pavel Vasilievich | Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing |
-
2000
- 2000-04-10 CN CN00819413A patent/CN1452482A/en active Pending
- 2000-04-10 AU AU2000263274A patent/AU2000263274A1/en not_active Abandoned
- 2000-04-10 WO PCT/RU2000/000122 patent/WO2001076583A1/en not_active Application Discontinuation
- 2000-04-10 BR BR0017206-5A patent/BR0017206A/en not_active IP Right Cessation
- 2000-04-10 JP JP2001574101A patent/JP3944393B2/en not_active Expired - Fee Related
- 2000-04-10 CA CA002404864A patent/CA2404864A1/en not_active Abandoned
- 2000-04-10 KR KR1020027013553A patent/KR20020089444A/en not_active Application Discontinuation
- 2000-04-10 EP EP00950127A patent/EP1272171A1/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003509349A5 (en) | ||
JP2021100937A5 (en) | ||
JP2004504406A5 (en) | ||
JP2003531118A5 (en) | ||
JP2009502743A5 (en) | ||
JP2004519469A5 (en) | ||
JP2008501705A5 (en) | ||
JP2006526590A5 (en) | ||
JP2006523216A5 (en) | ||
JP2001526218A5 (en) | ||
JP2002531505A5 (en) | ||
JP2005533860A5 (en) | ||
JP2006503850A5 (en) | ||
JP2002519425A5 (en) | ||
RU2004132856A (en) | PHARMACEUTICAL PRODUCT WITH MODIFIED RELEASE | |
JP2004532186A5 (en) | ||
JP2019515908A5 (en) | ||
JP2002527474A5 (en) | Medications for the treatment of mania and bipolar disorder | |
JP2005508337A5 (en) | ||
JP2009521473A5 (en) | ||
JP2010513487A5 (en) | ||
JP2002528502A5 (en) | ||
JP2002525323A5 (en) | ||
JP2003532640A5 (en) | ||
JP2001513506A5 (en) |